There are about 171 clinical studies being (or have been) conducted in Costa Rica. The country of the clinical trial is determined by the location of where the clinical research is being studied. Most studies are often held in multiple locations & countries.
The goal of the study is to determine if mamey sapote fruit, rich in rare potentially provitamin A keto-carotenoids, is a good source of vitamin A in humans. Furthermore, it will help to compare the absorption of carotenoids between the fruit versus a "matrix-free" formulation. The objective will be accomplished by quantitation of the immediate post-prandial plasma concentrations of parent carotenoids and vitamin A metabolites from participants consuming a meal consisting of a mamey sapote fruit smoothie or a shake containing mamey sapote encapsulated carotenoids.
Fluoropyrimidines are the backbone of chemotherapy regimes used to treat metastatic colorectal cancer (CRC). These drugs act in different pathways of folate metabolism altering DNA synthesis mainly by inhibition of the tymidylate synthase. For this reaction the 5,10-methylenetetrahydrofolate acts as cofactor. It has been demonstrated that A1298C and C677T polymorphisms in the methylenetetrahydrofolate reductase (MTHFR) gene result in reduced enzyme activity that leads to reduced availability of this important cofactor. Hence, we hypothesized that the presence of these polymorphisms are related to the efficacy and toxicity of fluoropyrimidines in patients with CRC.
Background: Cervical cancer is a dangerous disease caused by a germ called human papillomavirus (HPV). There are 3 safe vaccines that protect women against HPV and cancer. Currently, girls receive 2 doses of HPV vaccine. Researchers want to test if only 1 dose is enough. This study in Costa Rica is one of several new 1-dose studies being done around the world. Objective: To find out if giving only 1 dose of the HPV vaccine Cervarix to young girls works the same as giving 3 doses of the HPV vaccine Gardasil to young women. Eligibility: Healthy girls ages 9-14 Healthy women ages 18-25 Design: Participants will be screened with blood and urine tests and questions about their health. Their parents may answer some of the questions. Participants will get the vaccine as an injection in the arm. They will be observed for 15 minutes each time they get the vaccine. Participants ages 9-14 will get the Cervarix vaccine 1 time. Six months later, participants (or their parents) will be asked about their health. This contact will be a phone call and will take about 5 minutes. Participants ages 18-25 will get the Gardasil vaccine 3 times over 6 months. All participants will have 1 half-hour visit every year for 3 years after getting the vaccine. This can be at the clinic or the participant s home. Participants and/or their parents will answer questions about the participant s health and any vaccines they received since the last contact. Participants will give a blood sample.
This study will evaluate the safety, pharmacokinetics and efficacy of baloxavir marboxil in healthy pediatric participants from birth to <1 year with influenza like symptoms
This study will evaluate the safety, pharmacokinetics, and efficacy of baloxavir marboxil compared with oseltamivir in a single influenza episode in otherwise healthy pediatric participants (i.e., 1 to <12 years of age) with influenza-like symptoms.
To provide real world data on patient characteristics, disease management, healthcare utilization, and outcomes in patients with type 2 diabetes and established micro- and/or macrovascular disease
This study is a prospective, multicenter, open-label, single-arm effectiveness and safety study in participants with progressive multiple sclerosis (PMS).
The study develops, implements, and evaluates an intervention focused on alleviating discouragement, food insecurity, and excess weight in women,targeted at the individual, family, and community levels in the Canton Central of the province of Alajuela, Costa Rica.
In the BN40031 OLE study, a dose of crenezumab of 60 mg/kg IV Q4W will be offered to all patients who complete Study BN29552 or BN29553 and who meet eligibility criteria in order to evaluate safety in patients on long-term crenezumab treatment and to investigate the effect of crenezumab on the underlying disease process and disease course as an exploratory efficacy objective.
The main objectives of this observational cohort study are to describe the use of intravitreal aflibercept and to describe follow-up as well as treatment patterns in patients with wAMD or DME in routine clinical practice in Latin America for a study population of treatment naive patients and those who have received prior therapy (anti-VEGF injections, laser, steroids, etc.) and are being switched to intravitreal aflibercept injection.